Led · Series A · Mar 2024

URO-1’s core product is the patented SUREcore needle (U.S. Patent #11,903,569) and the coreCARE specimen retrieval kit, designed to obtain larger, more consistent and higher-quality biopsy cores. The company has focused initial commercialization on prostate biopsies and plans to expand into other areas of cancer diagnostics. URO-1 completed clinical validation over the past two years and received FDA clearance for SUREcore and coreCARE. The company intends to launch the SUREcore and coreCARE suite at the American Urological Association conference in early May and begin volume production this year. URO-1 was founded in 2017 and has been preparing to raise additional capital and build a production facility in Greensboro to support full-scale manufacturing. Financial milestones include a $250,000 Small Business Research Loan from the North Carolina Biotechnology Center in 2018 and completion of a Series A financing in early 2024.

Participated · Equity · Nov 2008

Eureka Therapeutics is a clinical-stage biotechnology company headquartered in the San Francisco Bay Area (Emeryville, Calif.) focused on developing novel T cell therapies for solid tumors. Its core technologies include the proprietary ARTEMIS® AbTCR T-cell receptor platform and the E-ALPHA® antibody discovery platform for discovery and development of potentially safer and more effective T cell therapies. The company’s lead asset, ET140202, is in a Phase I/II U.S. multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC). Eureka is advancing an anti-AFP ARTEMIS® Phase I/II clinical trial in the United States and is continuing development of its TCR-mimic and antibody-TCR ARTEMIS® programs. TCR-mimic antibodies are designed to recognize tumor-specific peptide/MHC complexes, enabling targeting of intracellular cancer-associated proteins that are not accessible to conventional antibodies or small molecules. The company will use proceeds from the Series E to accelerate these programs and clinical development. Eureka Therapeutics is a clinical-stage biotechnology company based in Emeryville, California, focused on improving the safety profile of T cell therapies and developing novel T cell therapies for hematological malignancies and solid tumors. Its core technologies include the proprietary ARTEMIS™ T cell receptor platform and the E-ALPHA® phage display library for discovery and engineering of human antibodies against intracellular targets via the MHC class I complex. The company is developing a pipeline targeting intracellular oncogenes as well as cell-surface antigens, with lead candidate ET190L1-ARTEMIS™ T cells in clinical development for relapsed and refractory CD19+ Non-Hodgkin Lymphoma. In November 2017 the U.S. FDA approved its IND and authorized a Phase I trial for ET190L1-ARTEMIS™, and Eureka expected to enroll the first patient at Duke University in Q1 2018. Eureka intends to use the Series D proceeds to advance ET190L1-ARTEMIS™ in that indication and to accelerate its broader immunotherapy pipeline against other hematological and solid tumors. The company is led by President and CEO Cheng Liu, PhD. Eureka Therapeutics is a Bay Area cancer immunotherapy company engineering monoclonal antibodies to mimic T cell receptors and recognize peptides from intracellular proteins presented on MHC. Its approach aims to target the roughly 90% of cancer-specific targets that are intracellular and traditionally considered undruggable. The company’s antibodies are designed to galvanize a patient’s immune system to attack and destroy cancer cells presenting those peptides. Eureka has a preclinical monoclonal antibody, ESK1, that targets the intracellular protein WT1 and was co-developed with Memorial Sloan‑Kettering Cancer Center. Earlier this year the company signed a license agreement with Novartis to develop and commercialize ESK1. Financially, Eureka recently completed a $21 million Series C to further advance its intracellular-targeting antibody programs. Eureka Therapeutics develops antibodies used to treat cancer. The company raised $6 million in a second-round financing to continue development of those antibodies. It also conducts outsourced antibody research services for other firms. The firm is based in Emeryville, Calif. Eureka previously completed a $1.6 million first round in 2006. The company is using the new financing to advance its antibody development programs.